Monte Rosa Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. The company is a pre-commercial biotechnology business developing small-molecule molecular glue degraders (MGDs) using its QuEEN platform. It reported no product revenue in the statements presented.
Financial results and position
| Metric | Q1 2023 | Q1 2022 / prior period |
|---|---|---|
| Research and development expense | $26.8 million | $17.9 million |
| General and administrative expense | $7.5 million | $6.4 million |
| Total operating expenses / operating loss | $34.3 million | $24.3 million |
| Net loss | $32.0 million | $23.9 million |
| Net loss per share, basic and diluted | $0.65 | $0.51 |
| Net cash used in operating activities | $23.4 million | $27.4 million |
| Cash, cash equivalents and marketable securities | $231.7 million | $262.8 million at December 31, 2022 |
| Total assets | $309.0 million | $342.4 million at December 31, 2022 |
| Total liabilities | $65.3 million | $71.0 million at December 31, 2022 |
Q1 operating cash outflow was partially offset by $20.3 million of net cash from investing activities, including marketable-security maturities and sales; financing activities provided $18,000. Cash, cash equivalents and restricted cash totaled $57.1 million at quarter-end. The company reported no debt or credit facility; it had $46.2 million of operating lease liabilities. Gross margin is not meaningful because the company has no reported product sales.
Changes versus the prior comparable period
Net loss increased by $8.1 million year over year as operating expenses rose $10.0 million. R&D expense grew $8.8 million, reflecting expanded research activity, personnel, facilities and laboratory costs; R&D headcount increased to 109 from 77. G&A expense increased $1.1 million. Higher interest income, up to $2.4 million from $0.1 million, partly offset expense growth. Operating cash use fell by $4.0 million year over year. Capital expenditures on property and equipment increased to $9.2 million from $1.7 million.
At March 31, the accumulated deficit was $262.6 million. Stockholders’ equity was $243.7 million, down from $271.4 million at year-end. No shares were sold under the company’s $100 million at-the-market program during Q1.
Outlook, risks and notable items
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital requirements for at least 12 months from issuance of the interim financial statements. It expects continuing losses and negative operating cash flows, and says additional funding will be needed for future research and development.
- The company expects R&D, G&A and capital expenditures to increase. Financing may involve equity, debt, collaborations, licenses or other arrangements; availability and terms are uncertain, and equity financing could dilute shareholders.
- Development priorities include the MRT-2359 GSPT1 program, including IND-enabling work and a clinical trial, as well as preclinical and discovery programs including NEK7, CDK2, VAV1 and sickle-cell-disease targets. The company cautions that drug development, regulatory approval and commercialization are uncertain.
- On April 12, 2023, the company amended its Basel Klybeck lease, increasing space from approximately 21,422 to 44,685 square feet and extending the term through June 30, 2027. The modification increased the right-of-use asset and lease liability by $1.8 million.
- The company reported no material litigation, no material change in internal control over financial reporting, and effective disclosure controls as of March 31, 2023. It said the COVID-19 pandemic had not significantly affected operations to date, while noting future effects remain uncertain.
Key facts for investors to verify
- Whether MRT-2359 clinical progress and other pipeline milestones match management’s plans, and their associated costs and timelines.
- Whether the stated liquidity runway remains achievable as operating expenses, facility costs and capital expenditures rise; the runway is based on assumptions that may prove incorrect.
- How much additional financing may be required, and whether it would cause dilution or impose debt-related restrictions.
- The financial and operating implications of the expanded Basel lease and the Boston laboratory build-out, including tenant-improvement reimbursements.
- The filing reports $231.7 million of cash, cash equivalents and marketable securities; restricted cash brings total cash, cash equivalents, restricted cash and marketable securities to $237.0 million.